Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

NCT06103838 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06103838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06103838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2024
Completion date
December 6, 2032
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, newly diagnosed multiple myeloma (ndmm), relapsed and/or refractory multiple myeloma (rrmm)